110 likes | 232 Views
Trial profile. Jonathan Mant, et al. Lancet 2007;370:493-503. Reasons why patients identified with atrial fibrillation did not take part in the study. Jonathan Mant, et al. Lancet 2007;370:493-503. Baseline characteristics of patients subsequently treated with warfarin or aspirin.
E N D
Trial profile Jonathan Mant, et al. Lancet 2007;370:493-503
Reasons why patients identified with atrial fibrillation did not take part in the study Jonathan Mant, et al. Lancet 2007;370:493-503
Baseline characteristics of patients subsequently treated with warfarin or aspirin Jonathan Mant, et al. Lancet 2007;370:493-503
Kaplan-Meier plot of adherence to allocated treatment Jonathan Mant, et al. Lancet 2007;370:493-503
Nature of primary events Jonathan Mant, et al. Lancet 2007;370:493-503
Kaplan-Meier plot of time to primary event Jonathan Mant, et al. Lancet 2007;370:493-503
Relative risk of all primary events by subgroup Jonathan Mant, et al. Lancet 2007;370:493-503
Risk of primary event and major haemorrhage by treatment allocation for different patient subgroups Jonathan Mant, et al. Lancet 2007;370:493-503
Risk of secondary and composite outcomes by treatment allocation for different patient subgroups Jonathan Mant, et al. Lancet 2007;370:493-503
Indirect comparison of results from BAFTA for ischaemic stroke and major haemorrhage with results from six other randomised trials of aspirin versus anticoagulation Jonathan Mant, et al. Lancet 2007;370:493-503